vaccines have been developed against the SARS-CoV-2 coronavirus. Effective drugs for a targeted COVID-19 treatment, on the other hand, do not yet exist. The research team led by Dr. Simon Krooss wants

National Pandemic Cohort Network (NAPKON) that has recruited several thousand patient suffering from COVID 19. In NAPKON he is head of the Biobank Core Unit (BCU) being responsible for different biosample

promotes severe COVID-19 disease. PLoS One. 2021;16:e0255335. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336874/ . Ackermann M, Jonigk DD. Microvascular placental alterations in a maternal COVID-19 infection [...] Langer F, Werlein C, Kuehnel MP, Jonigk D, Salditt T. 3D virtual histopathology of cardiac tissue from covid-19 patients based on phase-contrast X-ray tomography. Elife. 2021;10:10.7554/eLife.71359. https://pubmed [...] Welte T, Bauersachs J, David S, Bar C, Thum T. Circulating cardiovascular microRNAs in critically ill COVID-19 patients. Eur J Heart Fail. 2021;23:468-475. https://pubmed.ncbi.nlm.nih.gov/33421274/ . Hinkel

Association of maternal and midwifery characteristics with the number of postnatal home visits during the Covid-19 pandemic in Austria: a cross-sectional study Anja Chung: Der geplante hebammengeleitete Geburtsort [...] on of maternal and midwifery characteristics with the number of postnatal home visits during the Covid-19 pandemic in Austria: a cross-sectional study.

people - for example, after transplantation or severe respiratory illnesses such as influenza or COVID-19 – the fungus can enter the lungs and cause aspergillosis. The infection is particularly difficult

by the federal government, the state of Lower Saxony, the Helmholtz Association and the HZI. "The COVID-19 pandemic has just shown us how important infection research and personalised medicine are - and

The complication often occurs with cardiovascular diseases or severe infectious diseases - such as COVID-19 - but also after operations, when taking drugs that are harmful to the kidneys or as a result of

(RNA) has found its way into medicine, at the latest with the development of vaccinations against COVID-19. But RNA can be used for more than just vaccinations. It is also a promising molecule for developing

developed for use in biomedical research. "These systems are also already being used, for example in COVID-19 research," says the scientist. The main areas of research in the first funding period were, for

VPM1002 booster effect "VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including COVID-19 in the Elderly: a phase III randomised, double-blind, placebo-controlled, multicenter clinical